Exploring retroperitoneal fibrosis: Insights, challenges, and treatment approaches.
Ormond’s disease
Retroperitoneal fibrosis
idiopathic
ureterolysis
Journal
Urologia
ISSN: 1724-6075
Titre abrégé: Urologia
Pays: United States
ID NLM: 0417372
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
13
9
2024
Statut:
aheadofprint
Résumé
Retroperitoneal fibrosis (RPF) is a rare fibro-inflammatory condition characterized by abnormal tissue growth around the abdominal aorta and iliac arteries, usually encasing adjacent structures like the ureters. Its etiology remains most of the time idiopathic, but secondary causes, including malignancies and medication use, account for a minority of cases. This review aims to consolidate recent advancements in understanding RPF, focusing on its pathophysiology, diagnosis, and treatment. Literature search was conducted using databases like PubMed, with emphasis on recent publications. Biomarkers such as elevated CRP levels and imaging techniques like CT scans and MRI play pivotal roles in diagnosis and monitoring. Medical management primarily revolves around corticosteroids, with adjunctive therapies like tamoxifen and immunosuppressants showing promise. Surgical intervention, typically ureterolysis, becomes necessary in cases of urinary tract obstruction. This review studies the importance of a comprehensive approach to RPF management, integrating medical and surgical modalities for optimal patient outcomes.
Identifiants
pubmed: 39268704
doi: 10.1177/03915603241270453
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3915603241270453Déclaration de conflit d'intérêts
Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.